Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed participation in Part C of study ALN-AS1-001 (NCT02452372)~* Not on a scheduled regimen of hemin~* Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception~* Willing and able to comply with the study requirements and to provide written informed consent~Exclusion Criteria:~* Clinically significant abnormal laboratory results~* Received an investigational agent (other than ALN-AS1) within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Givosiran (Type: EXPERIMENTAL): At the beginning of this study, participants received either givosiran 2.5 mg/kg subcutaneous (SC) injection once monthly(QM), givosiran 5.0 mg/kg SC injection QM, or givosiran 5.0 mg/kg SC injection once every 3 months (Q3M). Within a year, all participants were transitioned to givosiran 2.5 mg/kg SC injection QM.

Based on this trial design, predict the completion outcome and termination type (if applicable).